British Patient Capital operates a £375m programme called Future Fund: Breakthrough, co-investing with private sector investors in R&D-intensive UK companies.
Eurazeo Growth led the extension round, backed by British Patient Capital and SEB, to support international expansion and product development.
"The prospect of transitioning to cloud native technology is now at the forefront of every major bank’s roadmap. Plans have been hastened in the wake of regulatory pressure, economic uncertainty and the need to manage cost-income ratios. Our flagship core banking product, Vault, brings the best in agility, resilience and security and is being used by major banks and fintech companies around the world. We are delighted to partner with Eurazeo Growth, British Patient Capital and SEB, which demonstrates ongoing investor interest in our technology and the significant market opportunity we are addressing."
Evolution Equity Partners led the Series C financing alongside participation from British Patient Capital, ABN AMRO Ventures, Dawn Capital, AlbionVC, HSBC and Accenture Ventures.
"We are thrilled that Evolution Equity Partners and British Patient Capital will be joining our team, alongside the strategic investment from ABN AMRO Ventures. Together with the continued trust and commitment from our existing investors, we will drive the next phase of Quantexa’s growth. We are seeing a huge demand for our platform to support multiple applications across our core markets in financial services and within new industry sectors. This investment will accelerate our product innovation roadmap and enable us to invest further into Europe, North America and Asia Pacific regions, as well as expand into new locations."
